Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate - Wikidata - wikimedia - TriplyDB

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

http://www.wikidata.org/entity/Q28383320

about

Potential use of histone deacetylase inhibitors in cancer therapy Predicting response to epigenetic therapy Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells Naturally Occurring Isothiocyanates Exert Anticancer Effects by Inhibiting Deubiquitinating Enzymes Molecular targets of isothiocyanates in cancer: recent advances No evident dose-response relationship between cellular ROS level and its cytotoxicity--a paradoxical issue in ROS-based cancer therapy.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells Targeting nrf2 signaling to combat chemoresistance.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation Metabolism as a key to histone deacetylase inhibition.Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages.Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.NADPH oxidase biology and the regulation of tyrosine kinase receptor signaling and cancer drug cytotoxicity An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts.Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications Stem cells, redox signaling, and stem cell aging.Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.Exploring the effects of isothiocyanates on chemotherapeutic drugs.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors.Histone Deacetylase Inhibitors as Anticancer Drugs.Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Involvement of endoplasmic reticulum stress in all-trans-retinal-induced retinal pigment epithelium degeneration.Mechanisms of resistance to apoptosis in the human acute promyelocytic leukemia cell line NB4.RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells.Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance.Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species.Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer.Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells.

P2860

Q26769594-7A3074E4-6839-4A21-A930-2146C7334F52 Q27027751-87FC4ABD-F42A-47D8-A252-D35CF4D739C8 Q28257534-E7A9D334-1087-4483-AE70-4B0090C7BC75 Q28269486-7A3BD028-C0A7-4233-9DC2-17568BF291C2 Q28307527-F71DDDF9-927B-4E0A-8726-A2DE37516AB3 Q33647236-F125992D-26F3-4913-87B5-810AED282602 Q33983255-2497E678-D9FE-4DBF-B43D-14987E30108C Q34221822-D5BBAA55-1273-4680-8B43-02D08A20E2EA Q34376139-AFA8284E-32C4-471B-A47D-7B7340584227 Q34488424-7FF87C73-2306-40BB-847C-21350994B7BB Q35126359-522CA48C-6997-4071-AC20-7C1CC2E13797 Q35661981-8D1E8252-75F4-4D5A-A936-5E2670ED7C4C Q35741605-F6A9D7F8-E069-45AF-8F71-854926D21185 Q35822102-70895720-09D9-4AE5-A235-FF923BD6D338 Q35975127-400FD726-6BFC-447D-A1C2-3661E8BA7E5F Q36224948-466B27B2-EBC7-4189-8B90-793B48E2F5E1 Q36342694-AC2ABFED-132A-4968-8888-01BFBBA4B29B Q36646486-7ADFFCED-2561-45FE-AB59-D8CCD7BDDD70 Q36656128-1DB9BA28-A60B-4DEF-8E06-402BDE91A111 Q36751751-3D7AF617-0849-4006-90B8-33B23CA3DAC6 Q36934314-EF647511-C401-493B-B333-FDCBF0987793 Q36970375-0ACEE591-EC8D-4926-8C9D-8FAB943052E2 Q37667604-181366EF-B812-42E4-A339-2CB6CD0C103D Q37813392-4F2EFCF2-4FEE-4B7B-8500-FC05C3AEE07B Q37821337-09161936-29E4-4833-84C6-710060A6DCC2 Q37873498-8D7DE17E-2F1D-4CB7-A836-2C371FF2F233 Q37902054-E95A475A-6348-42CA-AA14-442A2E6A07A1 Q37949185-657F847E-C91A-46C8-8227-49071D604A51 Q38148572-538E5438-2531-4187-8274-59CC080E3332 Q38240733-4D0F8CCB-9641-4CFD-B294-0EB6D8CD0949 Q38543089-C020A4A2-ADC3-4592-A313-A002231C5B8C Q38696932-AE04041E-150F-4946-9114-FD029C8D7A6E Q38710509-AA7611C3-560D-46C7-B68E-A75FEBF46685 Q38946467-865A5BA6-E8D3-4D52-BEC2-09CE22ADC355 Q38947220-86C3CC5A-846B-4AF3-B3D5-C815325D77CB Q39166818-B68C9D1B-C788-4AA2-95F3-C06801AF6024 Q39197858-34BF587A-EFE0-4D87-B6EB-D85399BA4A47 Q39251248-C50ECF03-391E-4A6A-BDE3-E82706BDA882 Q40129598-6643E369-44AC-4CD0-91BB-C95F0241C937 Q41084306-283C8E35-B573-45BD-99F6-FA8867F50430

P2860

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

http://www.wikidata.org/entity/Q28383320

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Overcoming resistance to histo ...... d β-phenylethyl isothiocyanate

@ast

Overcoming resistance to histo ...... d β-phenylethyl isothiocyanate

@en

Overcoming resistance to histo ...... d β-phenylethyl isothiocyanate

@nl

type

label

Overcoming resistance to histo ...... d β-phenylethyl isothiocyanate

@ast

Overcoming resistance to histo ...... d β-phenylethyl isothiocyanate

@en

Overcoming resistance to histo ...... d β-phenylethyl isothiocyanate

@nl

prefLabel

Overcoming resistance to histo ...... d β-phenylethyl isothiocyanate

@ast

Overcoming resistance to histo ...... d β-phenylethyl isothiocyanate

@en

Overcoming resistance to histo ...... d β-phenylethyl isothiocyanate

@nl

P1433

Q28383320-1AC7F715-2A8D-447B-B6D5-603CD46ADF5E

P1476

Q28383320-D332CDF9-F1A5-4CFA-9543-54D8BBF302E5

P2093

Q28383320-39426FB9-23CC-4B44-886C-6DB9AA752417

Q28383320-48978B7D-B498-4F39-959E-D630C3746C10

Q28383320-533BA523-1486-48F6-84A6-DE5D1917291C

Q28383320-6558A755-33B5-4433-B21F-823A0DB08796

Q28383320-7EEDE2E5-5E1B-4D20-98A6-582B24D0A83D

Q28383320-9329EACA-32C5-47C9-A6B4-7D127B231481

Q28383320-A6C40178-A2E2-4A67-A45B-7BF5A535D0AA

Q28383320-B61D7F3F-7B13-4583-8937-0160158B77EA

Q28383320-CEEAA40D-6E24-4B4B-8C8B-8064A2794595

Q28383320-D3B7444F-0864-41B2-B127-672863216EF5

P2860

Q28383320-1A50A8E9-E89E-4B98-A1BB-D944566FF91D

Q28383320-1B15DB19-AE7D-4161-A5CB-673299C7C9F5

Q28383320-1FCD269D-CCCD-4F5D-A352-4277C57B02F7

Q28383320-252289EB-7468-490D-9433-CE1D967A32E5

Q28383320-256F3B23-CA98-498F-9C64-E4D1D383319D

Q28383320-25DCE70D-2581-46E8-BDED-3551C0188D21

Q28383320-30DEA27F-4BA1-4384-BEF4-24DEFC3644C7

Q28383320-33BD8E9D-FDE4-4B4F-B06C-C2C35C6527D1

Q28383320-370D6B89-4613-43D9-BB14-0691822124F2

Q28383320-3FB59BFE-EC72-44D8-B486-D3AC2DEF65C9

P304

Q28383320-1007CB23-7B50-435A-AFAD-6831E6C00B64

P31

Q28383320-8C7D8DFB-90AA-4FE0-A9CE-53A3233F223D

P3181

Q28383320-403D72C5-0B40-4E28-A188-6204F9534246

P356

Q28383320-84E95246-1E71-439C-9823-C34D7DAE2761

P407

Q28383320-9F6D0C4C-12C9-474F-9245-0BFC9AE22D76

P433

Q28383320-4FFB7F7D-66D2-4085-82CD-3082E3BCA94E

P478

Q28383320-A55A99C3-C97E-49E6-AA5E-3677BA6B3A01

P50

Q28383320-6D4DD908-F21E-42A6-9535-6342633ACE0C

Q28383320-9A80B86D-299A-4FC1-9DE9-735CAD1FBD58

P577

Q28383320-CF05EE3A-C3AE-4D0B-BBE2-915263987616

P5875

Q28383320-E86EECA9-230A-4DD1-9F2F-178FCC21CB6F

P698

Q28383320-60A10E5A-057E-4826-9415-BEE4A188030A

P921

Q28383320-B6724214-72BB-4789-B362-97910F24DD7C

Q28383320-F4E1F87C-F5F2-4702-90B4-EA7EF11A8F7D

P932

Q28383320-6F5F1BC4-C77C-4384-8A92-29368E9E6808

P3181

P356

BLOOD-2009-11-256354

P1433

P1476

Overcoming resistance to histo ...... d β-phenylethyl isothiocyanate

@en

P2093

Gang Chen

http://www.w3.org/2001/XMLSchema#string

Hui Yang

http://www.w3.org/2001/XMLSchema#string

Hui Zhang

http://www.w3.org/2001/XMLSchema#string

Kapil Bhalla

http://www.w3.org/2001/XMLSchema#string

Peng Huang

http://www.w3.org/2001/XMLSchema#string

Wan Zhang

http://www.w3.org/2001/XMLSchema#string

Warren Fiskus

http://www.w3.org/2001/XMLSchema#string

Weiqin Lu

http://www.w3.org/2001/XMLSchema#string

Yu Jia

http://www.w3.org/2001/XMLSchema#string

Yue Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain

Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival

Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia

Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

NOX enzymes and the biology of reactive oxygen

Involvement of glutathione metabolism in the cytotoxicity of the phenethyl isothiocyanate and its cysteine conjugate to human leukaemia cells in vitro.

P304

2732-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1418263

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2009-11-256354

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Guillermo Garcia-Manero

Michael J. Keating

P577

2010-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44691363

http://www.w3.org/2001/XMLSchema#string

P698

20566897

http://www.w3.org/2001/XMLSchema#string

P921

P932

3324257

http://www.w3.org/2001/XMLSchema#string